Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



June 2004, Volume 34 Number 6 , p 30 - 30




  • Source

    The anticonvulsant drug topiramate (Topamax) can significantly reduce the frequency of a person's migraines, according to a new study. Plus, the drug's benefits begin the first month of treatment.

    In the study, 483 patients who typically experienced 3 to 12 migraines per month were randomly selected to receive either topiramate or a placebo for 26 weeks. Patients in the topiramate group were assigned to take one of three dosages: 50 mg/day, 100 mg/day, or 200 mg/day.

    Patients who took 100 mg/day or 200 mg/day of the drug had about two fewer migraines per month than before starting treatment and used less rescue medication. At these dosages, topiramate effectively reduced migraine frequency within the first month of treatment and the benefit continued for the duration of the study. Those taking the 50 mg/day dose of topiramate and those taking the placebo reported no significant reductions in migraine frequency.

    Regardless ...

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: